BioSpace News Archive

Peak Bio, Inc., is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Citi 18th Annual BioPharma Conference on Thursday, September 7, 2023, at 9:40 AM ET.

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) is pleased to announce that Harvest Medicine’s study entitled, “Self-Reported Effects of Illness Severity, Depression and Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series” has been published in the peer-reviewed American Journal of Endocannabinoid Medicine.

BioCare, Inc., a leading specialty pharmaceutical distribution partner known for its specialty distribution and logistics services, has once again secured a place on the Inc. 5000 list of fastest-growing private companies in America.

Rallybio Corporation announced its participation in the following upcoming investor conferences.

Pardes Biosciences, Inc. announced that MediPacific, Inc., an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc., has successfully completed the previously announced tender offer to acquire all of Pardes’ outstanding shares of common stock for a per share price of $2.13 in cash, plus a non-tradeable contingent value right associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.

Masimo and Franciscan Missionaries of Our Lady Health System, a 10-hospital system headquartered in Baton Rouge and serving communities throughout Louisiana and Mississippi, have signed a multi-year agreement to implement Masimo monitoring technologies system-wide.

Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET.

Femasys Inc. announced that it has obtained a Medical Device Establishment License from Health Canada.

Halozyme Therapeutics, Inc. announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences.